Patent EP0170623A2 successfully refreshed from Google Patents.
EP0170623A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Novel pharmaceutical use of (NVA)2-cyclosporine
Assignee: Novartis Pharma GmbH
•
Filing: 1985-07-24
•
Granted: —
•
Expires: 2005-07-24
Abstract
Abstract Novel pharmaceutical use for the compounds (Nva) 2 -and dihydro-(Val) 2- Cyclosporine, in particular their use in the treatment of autoimmune diseases selected from the group- consisting of: a) Uveitis; b) Juvenile diabetes type 1, c) Myasthenia gravis, d) Multiple sclerosis, e) Systemic lupus erythematosus, f) Haemolytic anaemia, and g) Glomerulonephritis.
Inventors
- 👤 Jean-François Borel
- 👤 Peter Donatsch
- 👤 Peter Hiestand
- 👤 Bernhard Ryffel
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 12:20
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/12; A61K38/13
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
71 words
A method for the treatment of an autoimmune disease selected from the group consisting of: a) Uveitis; b) Juvenile diabetes type I, c) Myasthenia gravis, d) Multiple sclerosis, e) Systemic lupus erythematosus, f) Haemolytic anaemia, and g) Glomerulonephritis; in a subject in need of such treatment, which method comprises administering to said subject an effective amount of (Nva)2-Cyclosporine or, in the case of disease a) or b) above, dihydro-(Val) 2 -Cyclosporine.
Claim 2
Independent Claim
71 words
A method for the treatment of an autoimmune disease selected from the group consisting of: a) Uveitis; b) Juvenile diabetes type I, c) Myasthenia gravis, d) Multiple sclerosis, e) Systemic lupus erythematosus, f) Haemolytic anaemia, and g) Glomerulonephritis; in a subject in need of such treatment, which method comprises administering to said subject an effective amount of (Nva)2-Cyclosporine or, in the case of disease a) or b) above, dihydro-(Val) 2 -Cyclosporine.
Claim 3
Dependent Claim
67 words
The use of (Nva) 2- Cyclosporine or of dihydro-(Val} 2- Cyclosporine for the treatment of an autoimmune disease selected from the group consisting of: a) Uveitis and b) Juvenile diabetes type I, or use of (Nva) 2- Cyclosporine for the treatment of an autoimmune disease selected from the group consisting of: c) Myasthenia gravis, d) Multiple sclerosis, e) Systemic lupus erythematosus, f) Haemolytic anaemia, and g) Glomerulonephritis.
Claim 4
Dependent Claim
67 words
The use of (Nva) 2- Cyclosporine or of dihydro-(Val} 2- Cyclosporine for the treatment of an autoimmune disease selected from the group consisting of: a) Uveitis and b) Juvenile diabetes type I, or use of (Nva) 2- Cyclosporine for the treatment of an autoimmune disease selected from the group consisting of: c) Myasthenia gravis, d) Multiple sclerosis, e) Systemic lupus erythematosus, f) Haemolytic anaemia, and g) Glomerulonephritis.
Claim 5
Dependent Claim
81 words
The use of (Nva) 2- Cyclosporine or of dihydro-(Val) 2- Cyclosporine for the manufacture of a pharmaceutical composition for the treatment of an autoimmune disease selected from the group consisting of: a) Uveitis, and b) Juvenile diabetes type I, or use of (Nva) 2- Cyclosporine for the manufacture of a pharmaceutical composition for the treatment of an autoimmune disease selected from the group consisting of: c) Myasthenia gravis, d) Multiple sclerosis, e) Systemic lupus erythematosus, f) Haemolytic anaemia, and g) Glomerulonephritis.
Claim 6
Dependent Claim
81 words
The use of (Nva) 2- Cyclosporine or of dihydro-(Val) 2- Cyclosporine for the manufacture of a pharmaceutical composition for the treatment of an autoimmune disease selected from the group consisting of: a) Uveitis, and b) Juvenile diabetes type I, or use of (Nva) 2- Cyclosporine for the manufacture of a pharmaceutical composition for the treatment of an autoimmune disease selected from the group consisting of: c) Myasthenia gravis, d) Multiple sclerosis, e) Systemic lupus erythematosus, f) Haemolytic anaemia, and g) Glomerulonephritis.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.